412 related articles for article (PubMed ID: 26510727)
21. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.
Eto T; Okubo Y; Momose A; Tamura H; Zheng R; Callendret B; Bastian AR; Comeaux CA
Influenza Other Respir Viruses; 2024 Jun; 18(6):e13336. PubMed ID: 38880785
[TBL] [Abstract][Full Text] [Related]
22. Single Immunization of a Vaccine Vectored by a Novel Recombinant Vaccinia Virus Affords Effective Protection Against Respiratory Syncytial Virus Infection in Cotton Rats.
Russell MS; Thulasi Raman SN; Gravel C; Zhang W; Pfeifle A; Chen W; Van Domselaar G; Safronetz D; Johnston M; Sauve S; Wang L; Rosu-Myles M; Cao J; Li X
Front Immunol; 2021; 12():747866. PubMed ID: 34603336
[TBL] [Abstract][Full Text] [Related]
23. Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
Green C; McGinley J; Sande C; Capone S; Makvandi-Nejad S; Vitelli A; Silva-Reyes L; Bibi S; Otasowie C; Sheerin D; Thompson A; Dold C; Klenerman P; Barnes E; Dorrell L; Rollier C; Pollard A; O'Connor D
Clin Exp Immunol; 2023 Mar; 211(3):269-279. PubMed ID: 36622786
[TBL] [Abstract][Full Text] [Related]
24. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.
Hayton EJ; Rose A; Ibrahimsa U; Del Sorbo M; Capone S; Crook A; Black AP; Dorrell L; Hanke T
PLoS One; 2014; 9(7):e101591. PubMed ID: 25007091
[TBL] [Abstract][Full Text] [Related]
25. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins.
Olszewska W; Suezer Y; Sutter G; Openshaw PJ
Vaccine; 2004 Nov; 23(2):215-21. PubMed ID: 15531040
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
[TBL] [Abstract][Full Text] [Related]
27. Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
Ascough S; Vlachantoni I; Kalyan M; Haijema BJ; Wallin-Weber S; Dijkstra-Tiekstra M; Ahmed MS; van Roosmalen M; Grimaldi R; Zhang Q; Leenhouts K; Openshaw PJ; Chiu C
Am J Respir Crit Care Med; 2019 Aug; 200(4):481-492. PubMed ID: 30753101
[No Abstract] [Full Text] [Related]
28. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
Fu YH; He JS; Wang XB; Zheng XX; Wu Q; Xie C; Zhang M; Wei W; Tang Q; Song JD; Qu JG; Hong T
Biochem Biophys Res Commun; 2010 Apr; 395(1):87-92. PubMed ID: 20350532
[TBL] [Abstract][Full Text] [Related]
29. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
30. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
31. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Folegatti PM; Bittaye M; Flaxman A; Lopez FR; Bellamy D; Kupke A; Mair C; Makinson R; Sheridan J; Rohde C; Halwe S; Jeong Y; Park YS; Kim JO; Song M; Boyd A; Tran N; Silman D; Poulton I; Datoo M; Marshall J; Themistocleous Y; Lawrie A; Roberts R; Berrie E; Becker S; Lambe T; Hill A; Ewer K; Gilbert S
Lancet Infect Dis; 2020 Jul; 20(7):816-826. PubMed ID: 32325038
[TBL] [Abstract][Full Text] [Related]
34. First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
Cicconi P; Jones C; Sarkar E; Silva-Reyes L; Klenerman P; de Lara C; Hutchings C; Moris P; Janssens M; Fissette LA; Picciolato M; Leach A; Gonzalez-Lopez A; Dieussaert I; Snape MD
Clin Infect Dis; 2020 May; 70(10):2073-2081. PubMed ID: 31340042
[TBL] [Abstract][Full Text] [Related]
35. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial.
Kotb S; Haranaka M; Folschweiller N; Nakanwagi P; Verheust C; De Schrevel N; David MP; Mesaros N; Hulstrøm V
Respir Investig; 2023 Mar; 61(2):261-269. PubMed ID: 36641341
[TBL] [Abstract][Full Text] [Related]
36. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.
Malkin E; Yogev R; Abughali N; Sliman J; Wang CK; Zuo F; Yang CF; Eickhoff M; Esser MT; Tang RS; Dubovsky F
PLoS One; 2013; 8(10):e77104. PubMed ID: 24204744
[TBL] [Abstract][Full Text] [Related]
37. Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
Leroux-Roels I; Van Ranst M; Vandermeulen C; Abeele CV; De Schrevel N; Salaun B; Verheust C; David MP; Kotb S; Hulstrøm V
J Infect Dis; 2024 Feb; 229(2):355-366. PubMed ID: 37699064
[TBL] [Abstract][Full Text] [Related]
38. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
[TBL] [Abstract][Full Text] [Related]
39. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.
Aliprantis AO; Shaw CA; Griffin P; Farinola N; Railkar RA; Cao X; Liu W; Sachs JR; Swenson CJ; Lee H; Cox KS; Spellman DS; Winstead CJ; Smolenov I; Lai E; Zaks T; Espeseth AS; Panther L
Hum Vaccin Immunother; 2021 May; 17(5):1248-1261. PubMed ID: 33121346
[TBL] [Abstract][Full Text] [Related]
40. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
